Cargando…
Improved and optimized drug repurposing for the SARS-CoV-2 pandemic
The active global SARS-CoV-2 pandemic caused more than 426 million cases and 5.8 million deaths worldwide. The development of completely new drugs for such a novel disease is a challenging, time intensive process. Despite researchers around the world working on this task, no effective treatments hav...
Autores principales: | Cohen, Sarel, Hershcovitch, Moshik, Taraz, Martin, Kißig, Otto, Issac, Davis, Wood, Andrew, Waddington, Daniel, Chin, Peter, Friedrich, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019610/ https://www.ncbi.nlm.nih.gov/pubmed/36928101 http://dx.doi.org/10.1371/journal.pone.0266572 |
Ejemplares similares
-
Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)
por: Egieyeh, Samuel, et al.
Publicado: (2021) -
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021) -
Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023) -
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021) -
Tackling SARS-CoV-2: proposed targets and repurposed drugs
por: Joshi, Siddhi, et al.
Publicado: (2020)